Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29399146 | 1.00 | PTPN22 (0.60) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| SCHEMBL8003535 | 1.00 | PTPN22 (0.60) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| SCHEMBL144495 | 1.00 | PTPN22 (0.60) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| SCHEMBL30168079 | 1.00 | PTPN22 (0.60) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| Hydrogen Sulfide SCHEMBL28776700 | 0.98 | PTPN22 (0.58) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| Methane SCHEMBL29209224 | 0.98 | PTPN22 (0.58) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| Sulfamide SCHEMBL3573443 | 0.90 | PTPN22 (0.55) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| Sulfuric Acid SCHEMBL7879258 | 0.90 | PTPN22 (0.50) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| SCHEMBL29484713 | 0.89 | HPRT1 (0.59) | PTPN22HSD17B10ALDH1A1TSHRHPGD | |
| SCHEMBL2466022 | 0.84 | ALDH1A1 (0.52) | PTPN22HSD17B10ALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271276-B | Naphthalenone derivative for promoting wound healing as well as preparation method and application thereof | 广州市朝利良生物科技有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-118271276-A | Naphthalenone derivative for promoting wound healing as well as preparation method and application thereof | 广州市朝利良生物科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118271276-B | Naphthalenone derivative for promoting wound healing as well as preparation method and application thereof | 广州市朝利良生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118271276-B | Naphthalenone derivative for promoting wound healing as well as preparation method and application thereof | 广州市朝利良生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118271276-A | Naphthalenone derivative for promoting wound healing as well as preparation method and application thereof | 广州市朝利良生物科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271276-A | Naphthalenone derivative for promoting wound healing as well as preparation method and application thereof | 广州市朝利良生物科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| CN-117355303-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4208021-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | Bio-Rad Laboratories, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116097093-A | Preparation of Nucleated RBC (NRBC) analogs for use as reference blood controls in automated blood analyzers | 生物辐射实验室股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-5789412-A | 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR ANTAGONISTS FOR THE CURATIVE OR PREVENTIVE TREATMENT OF PAIN, DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS, ANXIETY OR PANIC ATTACK, OR CANCER | PIERRE FABRE MEDICAMENT (FR) | 1998-08-04 | — | — | US | disclosed |
| EP-0813112-A1 | Photographic elements containing new magenta dye-forming couplers | EASTMAN KODAK COMPANY (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5670302-A | NAPHTHALENE COMPOUNDS SUBSTITUTED WITH HYDROXYL AND SECONDARY AMIDE GROUPS | EASTMAN KODAK COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-H753-H | RIGIDIZED OXAZOLE DYES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0034249-B1 | NEW NAPHTHIMIDAZOLE AND NAPHTHOXAZOLE DERIVATIVES, THEIR PREPARATION, AND THEIR USE IN PHARMACEUTICALS | GRUPPO LEPETIT S.P.A. (IT) | 1984-10-24 | — | — | EP | disclosed |
| US-4461894-A | Naphth[1,2-d]imidazoles | GRUPPO LEPETIT S.P.A. (IT) | 1984-07-24 | — | — | US | disclosed |
| US-4360674-A | Naphth[1,2-d]imidazoles | GRUPPO LEPETIT S.P.A. (IT) | 1982-11-23 | — | — | US | disclosed |
| EP-0034249-A2 | New naphthimidazole and naphthoxazole derivatives, their preparation, and their use in pharmaceuticals | GRUPPO LEPETIT S.P.A. (IT) | 1981-08-26 | — | — | EP | disclosed |
| US-4053312-A | O-SULFONAMIDONAPHTHOL DIFFUSIBLE DYE IMAGE PROVIDING COMPOUNDS | EASTMAN KODAK COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | HDAC3 555/4885PTPN22 4264/4885HSD17B10 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.